Holen Sie sich die Stockscreener-App
0.81
5.21%
0.0401
Handel nachbörslich:
.75
-0.06
-7.41%
Schlusskurs vom Vortag:
$0.7699
Offen:
$0.7593
24-Stunden-Volumen:
151.90K
Relative Volume:
0.17
Marktkapitalisierung:
$5.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.62M
KGV:
-0.1302
EPS:
-6.22
Netto-Cashflow:
$-7.93M
1W Leistung:
+0.00%
1M Leistung:
-2.01%
6M Leistung:
-12.90%
1J Leistung:
-30.77%
1-Tages-Spanne:
$0.73
$0.8199
1-Wochen-Bereich:
$0.73
$0.84
52-Wochen-Spanne:
$0.58
$1.73
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Firmenname
Hoth Therapeutics Inc
Sektor
Branche
Telefon
(646)756-2997
Adresse
590 MADISON AVENUE, NEW YORK, NY
Vergleichen Sie HOTH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
0.81 | 5.59M | 0 | -9.62M | -7.93M | -4.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2019-10-15 | Eingeleitet | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Aktie (HOTH) Neueste Nachrichten
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial - The Eastern Progress Online
Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study - The Eastern Progress Online
Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset - The Eastern Progress Online
EGFR Inhibitors-Induced Skin Disorders Market Growth - openPR
Hoth Up On Bitcoin Buy - MENAFN.COM
Hoth Up on Bitcoin Buy - Baystreet.ca
Hoth Therapeutics to purchase up to $1M of bitcoins as treasury reserve asset - MSN
Hoth Therapeutics Plans $1M Bitcoin Investment Following Board Approval | HOTH Stock News - StockTitan
Why Keysight Technologies Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Hoth Therapeutics shares hold buy as study shows cancer treatment promise - Investing.com India
Hoth Therapeutics Receives Notification from Nasdaq Due to Minimum Bid Price Non-Compliance - Defense World
Hoth Therapeutics faces Nasdaq delisting over stock price By Investing.com - Investing.com Australia
Hoth Therapeutics faces Nasdaq delisting over stock price - Investing.com
Hoth Therapeutics reports stable tumor growth in study By Investing.com - Investing.com Canada
Hoth Therapeutics Up 34% on Favorable Early Data for Preclinical Study of Cancer Drug - MarketWatch
Hoth Therapeutics reports stable tumor growth in study - Investing.com
Top investors say Hoth Therapeutics Inc (HOTH) ticks everything they need - SETE News
Hoth Therapeutics Inc [HOTH] Is Currently 8.11 above its 200 Period Moving Avg: What Does This Mean? - The DBT News
Hoth Therapeutics secures patent, analyst maintains steady target - Investing.com
Hoth Therapeutics secures patent, analyst maintains steady target By Investing.com - Investing.com UK
Hoth Therapeutics secures US patent for Alzheimer's drug By Investing.com - Investing.com Australia
HOTH’s Stock Market Adventure: -43.06% YTD Growth Amidst Volatility - The InvestChronicle
Hoth Therapeutics secures US patent for Alzheimer's drug - Investing.com India
Financial Metrics Check: Hoth Therapeutics Inc (HOTH)’s Ratios for Trailing Twelve Months - The Dwinnex
Hoth Shares Rise After Alzheimer's Treatment Gets Patent - MarketWatch
Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway - PR Newswire
Benchmark keeps Speculative Buy rating on Hoth shares on robust pipeline By Investing.com - Investing.com Canada
Benchmark keeps Speculative Buy rating on Hoth shares on robust pipeline - Investing.com
Hoth Therapeutics, Wise Systems Partner To Leverage AI For Drug Discovery - Contract Pharma
Micro Cap Already Off To The Races At The Bell - MSN
Hoth Therapeutics, Inc. (NASDAQ:HOTH) Sees Significant Increase in Short Interest - Defense World
Buy Honasa Consumer, target price Rs 530: JM Financial - The Economic Times
Examining the Potential Price Growth of Holley Inc (HLLY) - Knox Daily
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 4% - MarketBeat
Harrow Inc (HROW) Becoming More Attractive for Investors - Knox Daily
Davidson Kempner Capital Management LP Invests $3.21 Million in Loar Holdings, LLC (NYSE:LOAR) - Defense World
Why Investors Shouldn't Be Surprised By THOR Industries, Inc.'s (NYSE:THO) P/E - Simply Wall St
Lombard Odier Asset Management USA Corp Invests $786,000 in Hilton Grand Vacations Inc. (NYSE:HGV) - Defense World
THG Plunges 24% ATO amid Internal Frauds by Subsidiaries - KAOHOON INTERNATIONAL
Holley Inc. (NYSE:HLLY) Shares Sold by Kayne Anderson Rudnick Investment Management LLC - Defense World
Capstone Triton Financial Group LLC Has $707,000 Stock Position in Honeywell International Inc. (NASDAQ:HON) - Defense World
Hoth Therapeutics (NASDAQ:HOTH) Trading Down 3% - Defense World
Highbridge Capital Management LLC Purchases Shares of 630,114 HashiCorp, Inc. (NASDAQ:HCP) - MarketBeat
Haoxi Health Technology Down 75% After $12M Offering - MarketWatch
The time has not yet come to remove your chips from the table: Hoth Therapeutics Inc (HOTH) - SETE News
Hoth Therapeutics Inc (HOTH) gets rating Initiated from The Benchmark Company - Knox Daily
Hoth Therapeutics Inc [HOTH] Revenue clocked in at $0.00 million, down -25.69% YTD: What’s Next? - The DBT News
Balance Sheet Dive: Hoth Therapeutics Inc (HOTH)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Choreo LLC Purchases New Shares in The Hanover Insurance Group, Inc. (NYSE:THG) - Defense World
C4 Therapeutics Inc (NASDAQ: CCCC) Up 14.34% This Year: What To Expect Next - Stocks Register
Finanzdaten der Hoth Therapeutics Inc-Aktie (HOTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):